Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Non-contact and non-destructive detection and identification of Bacillus anthracis inside paper envelopes.

Kendler S, Aharoni R, Cohen S, Raich R, Weiss S, Levy H, Mano Z, Fishbain B, Ron I.

Forensic Sci Int. 2019 Aug;301:e55-e58. doi: 10.1016/j.forsciint.2019.05.007. Epub 2019 May 9.

PMID:
31153677
2.

A Rapid Antimicrobial Susceptibility Test for Determining Yersinia pestis Susceptibility to Doxycycline by RT-PCR Quantification of RNA Markers.

Shifman O, Steinberger-Levy I, Aloni-Grinstein R, Gur D, Aftalion M, Ron I, Mamroud E, Ber R, Rotem S.

Front Microbiol. 2019 Apr 16;10:754. doi: 10.3389/fmicb.2019.00754. eCollection 2019.

3.

The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans.

Tirosh A, Calay ES, Tuncman G, Claiborn KC, Inouye KE, Eguchi K, Alcala M, Rathaus M, Hollander KS, Ron I, Livne R, Heianza Y, Qi L, Shai I, Garg R, Hotamisligil GS.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaav0120. doi: 10.1126/scitranslmed.aav0120.

PMID:
31019023
4.

Combined Effect of Moringa oleifera and Ionizing Radiation on Survival and Metastatic Activity of Pancreatic Cancer Cells.

Hagoel L, Vexler A, Kalich-Philosoph L, Earon G, Ron I, Shtabsky A, Marmor S, Lev-Ari S.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419828829. doi: 10.1177/1534735419828829.

5.

Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer.

Conti S, Vexler A, Hagoel L, Kalich-Philosoph L, Corn BW, Honig N, Shtraus N, Meir Y, Ron I, Eliaz I, Lev-Ari S.

Integr Cancer Ther. 2018 Dec;17(4):1225-1234. doi: 10.1177/1534735418790382. Epub 2018 Jul 25.

6.

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP.

Breast Cancer Res Treat. 2016 Nov;160(2):305-312. Epub 2016 Oct 6.

7.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
8.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

9.

Curcumin induces apoptosis and inhibits growth of orthotopic human non-small cell lung cancer xenografts.

Lev-Ari S, Starr A, Katzburg S, Berkovich L, Rimmon A, Ben-Yosef R, Vexler A, Ron I, Earon G.

J Nutr Biochem. 2014 Aug;25(8):843-50. doi: 10.1016/j.jnutbio.2014.03.014. Epub 2014 Apr 13.

PMID:
24835302
10.
11.

Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway.

Rimmon A, Vexler A, Berkovich L, Earon G, Ron I, Lev-Ari S.

Biochem Res Int. 2013;2013:251752. doi: 10.1155/2013/251752. Epub 2013 Oct 27.

12.

Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells.

Berkovich L, Earon G, Ron I, Rimmon A, Vexler A, Lev-Ari S.

BMC Complement Altern Med. 2013 Aug 19;13:212. doi: 10.1186/1472-6882-13-212.

13.

[The role of medicinal herbs with anti-inflammatory properties in prevention and treatment of cancer].

Berkovich L, Ron I, Earon G, Abu-Ghanem S, Rimmon A, Lev-Ari S.

Harefuah. 2012 Nov;151(11):629-32, 654. Review. Hebrew.

PMID:
23367734
14.

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.

Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB.

J Skin Cancer. 2013;2013:828329. doi: 10.1155/2013/828329. Epub 2013 Jan 10.

15.

Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.

Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS.

J Immunother. 2012 Jan;35(1):73-7. doi: 10.1097/CJI.0b013e31823735d6.

PMID:
22130164
16.

The enigma of the E326K mutation in acid β-glucocerebrosidase.

Horowitz M, Pasmanik-Chor M, Ron I, Kolodny EH.

Mol Genet Metab. 2011 Sep-Oct;104(1-2):35-8. doi: 10.1016/j.ymgme.2011.07.002. Epub 2011 Jul 12. Review.

PMID:
21831682
17.

A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer.

Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O.

Oncologist. 2011;16(9):1197-202. doi: 10.1634/theoncologist.2011-0150. Epub 2011 Jun 28.

18.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
19.

Improved treatment of the breast and supraclavicular fossa based on a simple geometrical principle.

Yavetz D, Corn BW, Matceyevsky D, Ben-Josef R, Soyfer V, Bershtein I, Inbar M, Ron I, Jiveliouk I, Schifter D.

Med Dosim. 2011 Winter;36(4):434-9. doi: 10.1016/j.meddos.2010.11.001. Epub 2011 Mar 11.

PMID:
21397491
20.

Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines.

Maimon Y, Karaush V, Yaal-Hahoshen N, Ben-Yosef R, Ron I, Vexler A, Lev-Ari S.

J Int Med Res. 2010;38(6):2033-9.

PMID:
21227007
21.

Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.

Bendikov-Bar I, Ron I, Filocamo M, Horowitz M.

Blood Cells Mol Dis. 2011 Jan 15;46(1):4-10. doi: 10.1016/j.bcmd.2010.10.012. Epub 2010 Nov 23.

PMID:
21106416
22.

Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.

Ron I, Rapaport D, Horowitz M.

Hum Mol Genet. 2010 Oct 1;19(19):3771-81. doi: 10.1093/hmg/ddq292. Epub 2010 Jul 19.

PMID:
20643691
23.

Proteins as solid-state electronic conductors.

Ron I, Pecht I, Sheves M, Cahen D.

Acc Chem Res. 2010 Jul 20;43(7):945-53. doi: 10.1021/ar900161u.

PMID:
20329769
24.

Proteins as electronic materials: electron transport through solid-state protein monolayer junctions.

Ron I, Sepunaru L, Itzhakov S, Belenkova T, Friedman N, Pecht I, Sheves M, Cahen D.

J Am Chem Soc. 2010 Mar 31;132(12):4131-40. doi: 10.1021/ja907328r.

PMID:
20210314
25.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ.

Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11.

26.

Invasive breast cancer treated with taxol and epirubicin neo-adjuvant chemotherapy: the role in the outcome of the "crosstalk" between Erb receptors and p53.

Sarid D, Ron IG, Shoshan L, Barnea I, Shina S, Baratz M, Greenberg J, Merimsky O, Ben-Yosef R, Lev-Ari S, Keidar Y, Yaal-Hahoshen N.

Anticancer Res. 2008 Sep-Oct;28(5B):3147-52.

27.

Selective electroless deposition of metal clusters on solid-supported bacteriorhodopsin: applications to orientation labeling and electrical contacts.

Ron I, Friedman N, Cahen D, Sheves M.

Small. 2008 Dec;4(12):2271-8. doi: 10.1002/smll.200800524.

PMID:
19016493
28.

Breast metastasis from a renal cell carcinoma.

Bortnik S, Cohen DJ, Leider-Trejo L, Ron IG.

Isr Med Assoc J. 2008 Oct;10(10):736-7. No abstract available.

29.

Bacteriorhodopsin as an electronic conduction medium for biomolecular electronics.

Jin Y, Honig T, Ron I, Friedman N, Sheves M, Cahen D.

Chem Soc Rev. 2008 Nov;37(11):2422-32. doi: 10.1039/b806298f. Epub 2008 Sep 19. Review.

PMID:
18949115
30.

Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?

Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, Yaal-Hahoshen N.

Isr Med Assoc J. 2008 May;10(5):339-43.

31.

Covalent attachment of bacteriorhodopsin monolayer to bromo-terminated solid supports: preparation, characterization, and protein stability.

Jin Y, Girshevitz O, Friedman N, Ron I, Cahen D, Sheves M.

Chem Asian J. 2008 Jul 7;3(7):1146-55. doi: 10.1002/asia.200700403.

PMID:
18484563
32.

Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients.

Ron I, Horowitz M.

Mol Genet Metab. 2008 Apr;93(4):426-36. Epub 2007 Dec 21.

PMID:
18160322
33.

Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.

Clin Drug Investig. 2006;26(12):691-701.

PMID:
17274676
34.

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.

Safra T, Ron I, Boaz M, Brenner J, Grisaru D, Inbar M, Hayat H, Menczer J, Golan A, Levy T.

Acta Oncol. 2006;45(4):463-8.

PMID:
16760183
35.

One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.

Safra T, Kovner F, Barak N, Inbar MJ, Ron IG.

Isr Med Assoc J. 2006 Jan;8(1):27-9.

PMID:
16450747
36.

A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.

Ron IG, Sarid D, Ryvo L, Sapir EE, Schneebaum S, Metser U, Asna N, Inbar MJ, Safra T.

Melanoma Res. 2006 Feb;16(1):65-9.

PMID:
16432458
37.

ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.

Ron I, Horowitz M.

Hum Mol Genet. 2005 Aug 15;14(16):2387-98. Epub 2005 Jul 6.

PMID:
16000318
38.

Use of fluorescent substrates for characterization of Gaucher disease mutations.

Ron I, Dagan A, Gatt S, Pasmanik-Chor M, Horowitz M.

Blood Cells Mol Dis. 2005 Jul-Aug;35(1):57-65.

PMID:
15916907
39.

Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.

Asna N, Lewy H, Ashkenazi IE, Deutsch V, Peretz H, Inbar M, Ron IG.

Life Sci. 2005 Mar 4;76(16):1825-34. Epub 2005 Jan 28.

PMID:
15698860
40.

Functional optical detection based on pH dependent fluorescence lifetime.

Gannot I, Ron I, Hekmat F, Chernomordik V, Gandjbakhche A.

Lasers Surg Med. 2004;35(5):342-8.

PMID:
15611954
41.

The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases.

Ron IG, Stav O, Vishne T, Evan-Sapir E, Soyfer V, Agai R, Cherny N, Kovner F.

Am J Clin Oncol. 2004 Oct;27(5):500-4.

PMID:
15596920
42.

[Hormone replacement therapy in breast cancer survivors: the Israeli Society for Clinical Oncology and Radiotherapy policy letter].

Siegelmann-Danieli N, Ron I, Kaufman B, Uzieli B, Karminsky N, Inbar M; Israeli Society for Clinical Oncology and Radiotherapy.

Harefuah. 2004 Oct;143(10):753-6, 764. Hebrew.

PMID:
15521355
43.

Cutaneous and subcutaneous metastases of rectal cancer.

Sarid D, Wigler N, Gutkin Z, Merimsky O, Leider-Trejo L, Ron IG.

Int J Clin Oncol. 2004 Jun;9(3):202-5.

PMID:
15221607
44.

Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E.

J Nucl Med. 2004 Feb;45(2):272-8.

46.

[Hormone replacement therapy in breast cancer survivors: the Israeli Society for Clinical Oncology and Radiotherapy policy letter].

Siegelmann-Danieli N, Ron I, Kaufman B, Uzieli B, Karminsky N, Inbar M; Israeli Society for Clinical Oncology and Radiotherapy.

Harefuah. 2002 Nov;141(11):994-6, 1008. Hebrew.

PMID:
12476637
47.

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.

Ron IG, Wigler N, Borovik R, Peretz T, Rizel S, Shani A, Brenner J, Farbstein H, Brenner HJ, Chaitchik S, Catane R, Inbar MJ.

Am J Clin Oncol. 2002 Oct;25(5):520-2.

PMID:
12393997
48.

Spontaneous regression of retroperitoneal metastases from a primary pure anaplastic seminoma: a case report.

Sarid DL, Ron IG, Avinoach I, Sperber F, Inbar MJ.

Am J Clin Oncol. 2002 Aug;25(4):380-2.

PMID:
12151969
49.

A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy.

Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y.

Eur J Cancer. 2002 Jul;38(11):1490-4.

PMID:
12110495

Supplemental Content

Support Center